24 results
424B5
IPHA
Innate Pharma
6 Feb 24
Prospectus supplement for primary offering
5:00pm
million (for an individual).
In the context of the ongoing COVID-19 pandemic, the Decree (décret) n°2020-892 dated July 22, 2020 (as modified
F-3
IPHA
Innate Pharma
20 Dec 23
Shelf registration (foreign)
4:45pm
million (for an individual).
In the context of the ongoing COVID-19 pandemic, the Decree (décret) n°2020-892 dated July 22, 2020 (as modified by the Decree
6-K
EX-99.2
IPHA
Innate Pharma
14 Sep 23
Innate Pharma Reports First Half 2023 Financial Results and Business Update
6:27am
of the package of measures put in place by the French government to support companies during the COVID-19 pandemic. In August 2022, the Company has
424B5
f3b58d cv8
26 Apr 23
Prospectus supplement for primary offering
4:01pm
6-K
EX-99.2
eol 4buk7
15 Sep 22
Innate Pharma Reports First Half 2022 Financial Results and Business Update
6:12am
424B5
f5nu1546njv
3 May 22
Prospectus supplement for primary offering
4:36pm
6-K
EX-99.1
idq60 iqi
5 Jan 22
Financing strengthens Company’s cash horizon
6:00am
6-K
EX-99.2
8rymm2t8w6sm 83f
15 Sep 21
Innate Pharma Reports First Half 2021 Financial Results and Business Update
6:07am
6-K
EX-99.1
qs0wyxdp
12 May 21
Innate Pharma Virtual 2021 Annual General Meeting
6:30am
F-3
w1ghm6bz4
13 Jan 21
Shelf registration (foreign)
1:59pm
6-K
EX-99.1
0ckw ovj0pz
11 Dec 20
Current report (foreign)
6:30am
6-K
EX-99.1
bqnjdjho
17 Nov 20
Innate Pharma Reports Third Quarter 2020 Financial Results and Business Update
6:30am
6-K
EX-99.1
mg2q7tq90mh5j046c6y4
8 Sep 20
Innate Pharma Reports First Half 2020 Financial Results and Business Update
6:10am